Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E to castration resistant prostate cancer patients

Trial Profile

Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E to castration resistant prostate cancer patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2016

At a glance

  • Drugs GEN 0101 (Primary) ; GEN 0101 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association (2016) .
    • 25 Sep 2012 Planned end date (1 Aug 2014) as reported by University Hospital Medical Information Network - Japan.
    • 23 Nov 2011 trial appears to be underway according to an AnGes MG media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top